Methadone Pharmacokinetics in Cardiac Surgery

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-70
SponsorWake Forest University Health Sciences

About this trial

Cardiac surgery frequently leads to significant postoperative pain, with multiple different drug regimens being utilized (both opioid and non-opioid) in an attempt to alleviate this surgical pain. Methadone is currently one of the drugs that is being utilized to help control the pain. It can be given during and/or after surgery. This study hopes to identify the optimal dose of methadone to use to treat this surgical pain.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Elective cardiac surgery requiring median sternotomy and cardiopulmonary bypass (CABG, valve, combined CABG/valve surgeries)

Anticipated extubation within 12 hours postoperatively

No prior opioid use within 30 days of surgery

Ability to provide informed consent

Disqualifiers

Severe liver or kidney dysfunction (Child-Pugh class B/C, eGFR <30 mL/min/1.73m², creatinine >2 mg/dL, dialysis)

Allergy to methadone or fentanyl

Use of CYP3A4 inducers (rifampin, phenytoin, carbamazepine), CYP3A4 inhibitors (ketoconazole, erythromycin, clarithromycin, itraconazole), SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine)

Body mass index >40 kg/m²

Trial design

Design model

Parallel

Treatments tested in this trial

  • Single dose of methadone

    Drug

    Single dose of methadone 0.3 mg/kg actual body weight (max 30 mg) administered at induction of anesthesia

  • Split dose of methadone

    Drug

    Split dose of methadone 0.2 mg/kg actual body weight at induction and 0.1 mg/kg actual body weight post cardiopulmonary bypass

  • Balanced split dose of methadone

    Drug

    Balanced split dose of methadone 0.15 mg/kg actual body weight at induction and 0.15 mg/kg actual body weight post cardiopulmonary bypass

Treatment groups

69 Participants
are divided into 3 treatment groups
Group A: Single dose of methadoneActive comparator 1 intervention
Group B: Split dose of methadoneExperimental treatment 1 intervention
Group C: Balanced split dose of methadoneExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Plasma methadone concentration (ng/mL) 10 min post initial dose

Plasma methadone concentration will be measured 10 minutes post initial methadone dose

Time frame
10 minutes
2

Plasma methadone concentration (ng/mL) 30 min post initial dose

Plasma methadone concentration will be measured 30 minutes post initial methadone dose pre cardiopulmonary bypass

Time frame
30 minutes
3

Plasma methadone concentration (ng/mL) 60 min post initial dose

Plasma methadone concentration will be measured 60 minutes post initial methadone dose pre cardiopulmonary bypass

Time frame
60 minutes
4

Plasma methadone concentration (ng/mL) 10 min post start of cardiopulmonary bypass

Plasma methadone concentration will be measured 10 minutes after cardiopulmonary bypass started

Time frame
10 minutes

Secondary outcomes

1

pain intensity score

Pain intensity score will be measured using the visual analog scale. Scores will be measured on a scale of 0-10, with 0=no pain and 10=most severe pain

Time frame
2, 4, 8, 12, 24, 48, and 72 hours postoperatively and month 3
2

patient global impression of change

Patient Global Impression of Change will be used to assess patient-perceived analgesic effectiveness and overall postoperative recovery. Total score range is 1-7 with a higher score indicating considerable improvement with treatment.

Time frame
24, 48, and 72 hours after removal of the breathing tube
3

postoperative opioid consumption

total postoperative opioid consumption in morphine milligram equivalents

Time frame
up 72 hours postop
4

duration of postoperative mechanical ventilation

number of minutes with postoperative mechanical ventilation

Time frame
up to 72 hours postop

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: